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Abstract 
Purpose: To investigate the effect of withaferin A (WFA) on the proliferation and migration of brain 
endothelial cells.  
Methods: BALB-5023 mouse microvascular cells were treated with a range of withaferin A (WFA) 
concentrations from 10 to 100 ng/mL. Dojindo’s CCK-8 cell proliferation kit was used for the analysis of 
cell proliferation. Transwell cell culture inserts were used to determine the migration potential of WFA-
treated endothelial cells. Absorbance was measured at 450 nm on an enzyme-linked immunosorbent 
(ELISA) reader. 
Results: The results revealed a significant increase in the proliferation and migration of endothelial cells 
following treatment with a low concentration (30 ng/mL) of WFA compared with the higher concentration 
(> 10 ng/mL). The effect was further enhanced when WFA was used in combination with soluble Fas 
ligand (sFasL). Autocrine signaling of vascular endothelial growth factor (VEGF) by endothelial cells 
was significantly increased following treatment with WFA or in combination with sFasL. WFA increased 
the expression of Fas on endothelial cells, suggesting the involvement of sFasL in the proliferation and 
migration of brain endothelial cells.  
Conclusion: Thus, WFA promotes the proliferation and migration of endothelial cells through increase 
in the expression of Fas and secretion of VEGF.  
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At present the leading cause of morbidity and 
mortality throughout the globe is cardiovascular 
diseases and stroke. Endothelial cells form the 
covering of the vascular lumen of peripheral 
organs and the central nervous system. These 
cells produce and release substances that relax 
or constrict the blood vessels, which may 
contribute to the development of vascular failure 
[1]. To maintain the necessary supply of 
metabolic and functional requirements to various 
tissues formation of new blood vessels or 
angiogenesis has a vital role. Angiogenesis 
involves the proliferation and migration of 
endothelial cells [2]. The immune compromised 
mice with stroke on administration of human cord 
blood-derived CD34+ cells develop 
neovascularization in the ischemic zone and 
provide a favourable environment for neuronal 
regeneration [3]. It is reported that circulating 
CD34+ endothelial progenitor cells participate in 
neovascularization in ischemic tissues [4,5]. But 
the outgrowth of pre-existing vasculature is 
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assumed to be indispensable in the postnatal 
development of neovessels. Therefore the 
proliferation and migration ability of endothelial 
cells is vital for the recovery of vascular 
diseases, including cardiovascular diseases and 
stroke. 
 
Withaferin A [1], a steroidal lactone is isolated 
from Withania somnifera, the extracts of which 
are used in traditional East Indian medicine [6]. 
Among the withanolides isolated from W. 
somnifera, withaferin A is present as a dominant 
compound [7,8]. Withaferin A has anti-angiogenic 
effect [6, 9] at micromolar doses and inhibits soft 
tissue sarcoma growth and local recurrence in 
xenograft experiments [10]. It is reported to have 
proapoptotic and anti-tumor activity in breast and 
prostate cancers [11-13]. Withaferin A acts on 
NF-Kb, BCL-2, FOXO3A, Hsp90, phosphorylated 
STAT3 and annexin II [12,14-18]. Taking cue 
from the literature, we designed an experiment to 
study the effect of withaferin A on suppression of 
brain tumor growth in a nude mice model with an 




Cell line and culture 
 
The mouse brain microvascular endothelial cell 
line, BALB-5023 was purchased from the 
American Type Culture Collection (Manassas, 
VA, USA). The cells were grown in complete 
medium consisting of DMEM Gluta MAX, 
supplemented with 1 % penicillin/streptomycin 
and 10 % FCS (Gibco-BRL, Melbourne, 
Australia). 
 
Endothelial cell proliferation assay 
 
For effects on cell proliferation, Dojindo’s CCK-8 
cell proliferation kit (Dojindo Molecular 
Technologies, Japan) was used. Briefly, 1 × 105 
cells in 100 μL complete medium were seeded 
into each well of a 96-well plate. After 24 h, 
different concentrations of WFA (Chinese 
National Institute for the Control of 
Pharmaceutical and Biological Products, Beijing, 
China) or soluble FasL (Sigma, St. Louis, MO, 
USA) were added to each well containing 
endothelial cells for 48 h. 20 μL of CCK-8 
solution (5 mg/mL; Dojindo, Kumamoto, Japan) 
was added into each well after incubation for 48 
h. The cells were then incubated for 4 h more. A 
Multiskan Go spectrophotometer (Thermofisher 
Scientific, USA) was employed to measure the 
cell proliferation at 450 nm.The proliferation 
index was calculated using the equation 1. 
 
(OD450 in the presence of WFA - OD450 in the 
blank control)/OD450 in the blank control × 100 
%………………………………………………1 
 
Endothelial cell migration assay 
 
Transwell cell culture inserts were used to 
determine the migration potential of WFA treated 
endothelial cells. The upper chambers of the 
inserts were seeded with 2 × 105 cells in 200 mL 
serum-free DMEM whereas the lower chamber 
was filled with 750 mL of DMEM containing 20 % 
FBS as a chemoattractant except in control wells 
which contained serum-free DMEM in both upper 
and lower chambers. After 24 h of incubation in a 
humidified incubator with 5 % CO2 the non-
migrated cells in the upper chamber were 
swabbed off. The plates were fixed, stained, and 
then observed under an inverted fluorescent 
microscope. Five field views were randomly 
counted in triplicates and averaged. 
 
ELISA for VEGF 
 
In 6-well plates, endothelial cells were treated for 
72 h with either WFA or WFA and soluble FasL. 
The supernatant was collected and stored at -80 
oC. For VEGF, ELISA (R&D Systems, 
Minneapolis, MN, USA) was performed as per 
the manufacturer's protocol. To each well 100 μl 
assay diluents, followed by 100 μl standard, 
control or cell culture supernatant was added. 
The plates were incubated at room temperature 
for 2 h followed by aspiration and washing. 
Thereafter, 100 μL conjugated secondary 
antibody was added into each well for 2 h at 
room temperature. After washing, 100 μL of 
substrate solution was added to each well for 30 
min at room temperature. Finally, 100 μL of stop 
solution was added and the absorbance was 
read at 450 nm on an ELISA reader (Bio-Rad, 
Hercules, CA, USA) within 30 min. All readings 
were performed in triplicates. 
 
Western blotting for Fas protein 
 
The cells treated with WFA alone or combined 
with soluble FasL for 72 h were washed twice in 
PBS followed by addition of Lysis buffer (50 mM 
Tris-HCl pH 7.4, 137 mM NaCl, 10 % glycerol, 
100 mM sodium vanadate, 1 mM PMSF, 10 
mg/ml aprotinin, 10 mg/mL leupeptin, 1 % NP-40, 
and 5 mM cocktail). Bicinchoninic acid assay 
(BCA) method was used to determine protein 
concentration. Equal amounts of protein were 
loaded and resolved by electrophoresis on a 10 
% polyacrylamide gel. The semi-dry method was 
used to transfer proteins onto a polyvinylidene 
difluoride (PVDF) membrane which was then 
blocked with 5 % non-fat dry milk overnight. After 
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Tris-buffered saline Tween-20 (TBST) washing, 
membrane was incubated for 2 h with anti-Fas 
(dilution 1:2,000; KeyGen Biotech, Nanjing, 
Jiangsu, China) and then washed again with 
TBST before incubation with secondary 
antibodies for 2 h. Antigen was detected using 
enhanced chemiluminescence (Pierce 
Biotechnology, Inc, Rockford, IL, USA). All the 




Each assay was performed in triplicate. The data 
are expressed as mean ± standard deviation 
(SD). SPSS 16 software was used for all 
statistical analyses. One-way analysis of 
variance (ANOVA) was used to determine 
significant differences. Statistical significance 




Proliferation of endothelial cells stimulated 
by low-dosage WFA 
 
The endothelial cells were treated with a range of 
WFA concentrations and analysed by CCK-8 cell 
proliferation assay kit. The results revealed that 
WFA stimulated the proliferation of the 
endothelial cells significantly at a low-dosage, 
ranging from 0.025 to 0.25 ng/mL, compared to 
the control cells (p < 0.05). However, treatment 
of the cells with WFA at higher dosage (> 100 
ng/mL), resulted in the cell impairment (Figure 1). 
Thus, 0.25 ng/mL WFA with sFasL was used to 
analyse the combined effects. 
 
Effect of sFasL on the WFA stimulated 
proliferation of endothelial cells 
 
Treatment of the endothelial cells with WFA at 
0.25 ng/mL induced the cell division. sFasL at 
the concentration of 0.16 ng/mL also induced the 
proliferation of endothelial cells through Fas-
FasL pathway. However, the proliferation of 
endothelial cells was significantly higher on 
treatment with WFA and sFasL combination 
compared to WFA alone (p < 0.05; Figure 2). 
 
WFA combined with sFasL enhances the 
migration of endothelial cells  
 
The transwell cell culture inserts were used to 
study the effect of WFA on the endothelial cell 
migration. The results revealed that WFA 
promoted the proliferation of endothelial cells. 
Endothelial cell migration is also essential for 
angiogenesis. In the present study, WFA could 
also enhance the migration of endothelial cells, 
which is more evident if combined with sFasL (p 
< 0.05; Figure 3). 
 
 
Figure 1: WFA induced proliferation of endothelial cells. Different doses of WFA (0-500 ng/mL and 10-100 
ng/mL) were tested for its effect on the proliferation of endothelial cells. WFA at the lower dose (20-500 ng/mL) 
induced proliferation, whereas overdose (10-100 ng/mL) significantly inhibited cell growth. WFA, withaferin A 
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Figure 2: sFasL enhanced WFA induced proliferation of the endothelial cells. WFA at 30 ng/mL or WFA and 
sFasL, were used in combination for the cell culture; sFasL significantly enhanced the WFA-induced proliferation 
of the endothelial cells, which was dose dependent. sFasL, soluble Fas ligand; WFA, withaferin A 
 
 
Figure 3: WFA in combination with sFasL enhanced the migration of endothelial cells. (A) WFA alone or 
combination of WFA and sFasL increased the migration of endothelial cells. Representative images for each 
group, repeated at least four times. (B) Quantification of the migration of endothelial cells. sFasL, soluble Fas 
ligand; WFA, withaferin A 
 
Fas expression increases upon stimulation of 
WFA  
 
WFA and sFasL could promote the proliferation 
and migration of endothelial cells. In addition, 
WFA also increased the expression of Fas on 
endothelial cells (p < 0.05; Figure 4). 
 
WFA promotes the autocrine signaling of 
VEGF by endothelial cells 
 
The proliferation and migration of endothelial 
cells were mediated by VEGF. Accordingly, the 
endothelial cells secreted significantly more 
VEGF upon the stimulation of WFA. sFasL 
combination further increased the autocrine 




It is reported that WFA exhibits anti-angiogenic 
effect [12,15] at micromolar doses and inhibits 
soft tissue sarcoma growth and local recurrence 
in xenograft experiments [16]. Withaferin A can 
also inhibit the NO production by modulation 
iNOS. 
 
The present study demonstrates that WFA 
significantly enhanced the proliferation of the 
endothelial cells at a lower concentration (30 
ng/mL). However, at a concentration > 10 µM 
WFA exhibited reverse effect on the proliferation 
of endothelial cells in the physiological condition. 
It was observed that overdose of WFA had a 
harmful effect on the endothelial cells. In addition 
to enhanced cell proliferation, WFA also 
increased the migration of the endothelial cells. 
Both the enhanced cell proliferation and 
migration were significantly promoted by sFasL. 
The effect of WFA on Fas-FasL pathway in the 
endothelial cells was also examined. It is 
reported that Fas-FasL ligation induces 
proliferation of the endothelial cells by expressing 
the Fas-associated death domain protein and the 
Flice-like inhibitory protein (FLIP). 
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Figure 4: Fas expression increased upon the stimulation of WFA. BALB-5023 endothelial cells were treated with 
WFA (30 ng/mL) and the cell lysate was collected for the quantification of Fas. (A) Western blotting for the blank 
control or the WFA group; β-actin was used as an internal control. (B) Quantification of Fas was normalized to β-
actin and is expressed as the mean ± SEM (n = 3). WFA, withaferin A 
 
 
Figure 5: VEGF secretion by endothelial cells. WFA 
increased the autocrine signalling of VEGF by 
endothelial cells, which was further improved by the 
combination with sFasL. WFA, withaferin A; VEGF, 
vascular endothelial growth factor; sFasL, soluble Fas 
ligand 
 
FLIP recruits and activates the downstream 
molecules TNF-receptor-associated factor and 
nuclear factor κB (NF-κB). This down regulation 
finally induces the proliferation of the cells. 
Among the downstream molecules of the Fas-
FasL pathway NF-κB plays a vital role. In the 
present study, WFA directly up-regulated the 
expression of Fas, suggesting the underlying 




WFA promotes the proliferation and migration of 
endothelial cells and the effect is enhanced by 
combining it with sFasL. The effect of WFA on 
the endothelial cells is dependent on the 
increased expression of Fas and enhanced 
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